The Daily Start-Up: Amgen agrees to acquire KAI Pharmaceuticals

Amgen has announced it will acquire KAI Pharmaceuticals in a $315 million cash transaction, giving the drug maker rights to an experimental drug to treat chronic kidney disease.... [more]

View complete Wall Street Journal article